Biomarker-Driven Assessment of Immunochemotherapy with or without Fruquintinib as First-Line Treatment for Advanced Gastric/GEJ Adenocarcinoma: Initial Clinical Results and Subgroup Analysis from the MGC-FLORA Study (ESMO Asia 2026) - Oct 1, 2026 - Abstract #1067P; Pres time: Dec 4, 2026; 05:15 PM - 06:15 PM; Location: Poster area (Exhibition); No abstract available
Biomarker • Clinical • Metastases • Gastroesophageal Junction Adenocarcinoma • Oncology
|
|
Chenchen Wang; Xiaodong Zhu; Mingzhu Huang; Wanjing Feng; Jieyun Zhang; Yuedi Dai; Qin Ding
|